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Dysregulation of the inflammatory response can 
lead  to  diseases  such  as  rheumatoid  arthritis, 
Crohn’s disease, or septic shock. The cytokine 
IL-10 plays a role in limiting the magnitude, 
duration, and detrimental outcome of the in-
flammatory response (Moore et al., 2001). This 
was shown both with the generation of IL-10–
deficient mice that spontaneously develop in-
flammatory bowel disease (Kühn et al., 1993) 
and with the identification of patients with homo-
zygous mutations in the IL-10 receptor subunits 
who present with early-onset colitis (Glocker 
et al., 2009).
IL-10  is  produced  by  numerous  cells  in-
cluding Th1, Th2, Th17, T reg, CD8+ T cells, 
B cells, and myeloid cells (Saraiva and O’Garra, 
2010). One of IL-10’s key functions is the regu-
lation of pathogen-mediated activation of mac-
rophages and dendritic cells. It inhibits the   
T cell–activating potential of APC by down-
regulating MHC class II and the expression of 
costimulatory molecules such as CD80 and 
CD86 (Buelens et al., 1995). IL-10 also inhibits 
the expression of chemokines, inflammatory 
enzymes,  and  potent  proinflammatory  cyto-
kines such as TNF, the target for multiple clini-
cal strategies in rheumatoid arthritis and Crohn’s 
disease (Feldmann and Maini, 2003).
Although recent advances have lead to a 
greater understanding of the regulation of IL-10 
production (Saraiva and O’Garra, 2010), the 
precise mechanism of IL-10–dependent inhibi-
tion of TNF is less clear. Activation of STAT3, 
as a consequence of IL-10 binding to its cell 
surface receptor (IL-10R1/IL-10R2), is critical 
for  mediating  the  antiinflammatory  response 
(Takeda et al., 1999; Lang et al., 2002; Yasukawa 
et al., 2003; Williams et al., 2004a). However, 
mechanisms after STAT3 activation remain   
a controversial field. IL-10 has been shown to 
target  both  transcriptional  (Schottelius  et  al., 
1999; Murray, 2005) and posttranscriptional 
processes (Kontoyiannis et al., 2001; Denys 
et al., 2002; Schaljo et al., 2009) in a gene- 
specific  manner  (Lang  et  al.,  2002).  Many   
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IL-10 plays a central nonredundant role in limiting inflammation in vivo. However, the 
mechanisms involved remain to be resolved. Using primary human macrophages, we found 
that IL-10 inhibits selected inflammatory genes, primarily at a level of transcription.  
At the TNF gene, this occurs not through an inhibition of RNA polymerase II (Pol II) recruit-
ment and transcription initiation but through a mechanism targeting the stimulation of  
transcription elongation by cyclin-dependent kinase (CDK) 9. We demonstrated an un-
anticipated requirement for a region downstream of the TNF 3 untranslated region (UTR) 
that contains the nuclear factor B (NF-B) binding motif (B4) both for induction of 
transcription by lipopolysaccharide (LPS) and its inhibition by IL-10. IL-10 not only inhibits 
the recruitment of RelA to regions containing B sites at the TNF gene but also to those 
found at other LPS-induced genes. We show that although IL-10 elicits a general block in 
RelA recruitment to its genomic targets, the gene-specific nature of IL-10’s actions are 
defined through the differential recruitment of CDK9 and the control of transcription 
elongation. At TNF, but not NFKBIA, the consequence of RelA recruitment inhibition is a 
loss of CDK9 recruitment, preventing the stimulation of transcription elongation.
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comparing Pol II densities at the transcription start site (TSS) 
to the downstream region of TNF. As described by others 
(Adelman  et  al.,  2009;  Hargreaves  et  al.,  2009;  Ramirez- 
Carrozzi et al., 2009), Pol II was present at the TNF TSS under 
resting conditions and increased relatively weakly in response 
to LPS (Fig. 2 A). In contrast, it was scarcely detectable at   
the downstream region in resting cells and very strongly up- 
regulated by LPS, which is consistent with control of gene ex-
pression largely through the release of a block to transcription 
elongation. IL-10 weakly inhibited the LPS-induced increase 
of Pol II at the TSS but strongly inhibited the increase of Pol II 
at the distal region (Fig. 2 A and Fig. S1 B). Phosphorylation of 
Ser2 of the Pol II C-terminal domain (CTD) by CDK9 occurs 
during the transition from the initiation of transcription to elon-
gation (Price, 2000). We therefore performed ChIP using a 
phospho-Ser2–specific antibody. Where IL-10 did not inhibit 
the recruitment of total Pol II to the start of the TNF gene   
(Fig. 2 A; top left) it completely inhibited the phosphorylation 
of the Ser2 residue of the Pol II CTD (Fig. 2 A; bottom left). 
Therefore, at TNF the elongating form of Pol II is reduced by 
IL-10. When we conducted similar analysis at the NFKBIA 
gene, it was noted that neither the elongation of Pol II into the 
downstream region of the gene nor the phosho-Ser2 form of 
Pol II was decreased by IL-10 (Fig. 2 B).
We used the CDK9 inhibitor flavopiridol (Chao and Price, 
2001) to confirm that the phosphorylation of Ser2 of the Pol II 
CTD controls elongation at TNF. Flavopiridol had negligible 
effects on total Pol II recruitment to the start of TNF in contrast 
to its inhibition of Pol II Ser2 phosphorylation (Fig. 2 C). Ad-
ditionally, flavopiridol inhibited the accumulation of total Pol II 
at the downstream region of the TNF gene. These effects mir-
ror IL-10’s inhibition of Pol II phospho-Ser2 and elongation 
into the downstream regions of the gene (Fig. 2 A).
Interestingly, transcription elongation of NFKBIA was also 
sensitive to flavopiridol (Fig. S1 D), indicating that although   
IL-10 had no effect on elongation of NFKBIA, inhibiting the 
kinase activity of CDK9 with flavopiridol elicited a broader ef-
fect. Therefore it is unlikely that IL-10 has inhibitory effects on 
the kinase activity of CDK9 (as was the case for flavopiridol). 
We therefore looked at the effect IL-10 had on the recruitment 
of CDK9 itself to the TNF and NFKBIA genes (Fig. 2 D). At 
the start of TNF, CDK9 was recruited in a stimulus-dependent 
manner and this was inhibited by IL-10 (mean 47.2%; SEM   
6.5; n = 4). In contrast, at the start of NFKBIA, CDK9 was seen 
to be more constitutively associated, inducing only slightly in re-
sponse to LPS and exhibiting no inhibition upon IL-10 costimu-
lation. Recently, NFKBIA was described as a housekeeping 
primary response gene that is continuously transcribed in macro-
phages (Hargreaves et al., 2009), perhaps accounting for these 
differences. These differential effects on CDK9 recruitment be-
tween TNF and NFKBIA may underlie IL-10’s gene-specific, as 
opposed to general, inhibition of transcription elongation.
The current findings contradicted a previous observation 
from our laboratory, where the TNF 3 untranslated region 
(UTR) was required for IL-10 to suppress the TNF reporter 
gene activity (Denys et al., 2002). This implicated a mechanism 
studies of transcriptional effects have focused on the activity 
of NF-B, a dominant transcription factor in the production 
of inflammatory cytokines (Foxwell et al., 1998; Udalova   
et al., 1998). However, it remains unclear whether IL-10 inhib-
its NF-B activity (Wang et al., 1995; Schottelius et al., 1999; 
Denys et al., 2002; Murray, 2005; for reviews see Williams   
et al., 2004b; Grütz, 2005).
The variety of mechanisms proposed may reflect the use of 
mouse versus human systems or the use of genetically abnor-
mal transformed cell lines, and we have therefore confined our 
study to the use of primary human macrophages. We have 
found that inhibition is not only exerted on the process of pro-
inflammatory gene transcription but through a novel mecha-
nism of elongation inhibition, controlled in a gene-specific 
manner through the actions of cyclin-dependent kinase (CDK) 
9. IL-10 robustly inhibits RelA recruitment to B sites at mul-
tiple proinflammatory genes, and this results in an inhibition 
only at genes that are rapidly induced at a level of elongation 
by CDK9. These findings shed new light on the gene specific 
nature of the IL-10 antiinflammatory response.
RESULTS AND DISCUSSION
We initially examined the effects of IL-10 on LPS-induced 
mRNA expression in primary human macrophages. IL-10 in-
hibited TNF and IB- mRNA production at early and late 
time points and IL-6, a secondary response gene, at 120 min 
(Fig.  1  A).  IL-10  did  not  inhibit  the  production  of  IB- 
mRNA, which is consistent with the gene-specific effects previ-
ously described (Lang et al., 2002; Murray, 2005). A longstand-
ing question has been whether IL-10 inhibits gene expression at 
the transcriptional (Murray, 2005) or posttranscriptional level 
(Schaljo et al., 2009), or perhaps both (Denys et al., 2002), in ac-
tivated macrophages. Chromatin immunoprecipitation (ChIP) 
was used to measure accumulation of RNA polymerase II   
(Pol II) at distal regions of genes (Fig. 1 B), which is considered 
a hallmark of active transcription (Sandoval et al., 2004). LPS in-
duced rapid accumulation of Pol II at a distal region of the TNF 
gene and slower accumulation at a distal region of the IL6 gene 
(Fig. 1 C), which is consistent with the identification of these as 
primary and secondary response genes (Hargreaves et al., 2009; 
Natoli, 2009; Ramirez-Carrozzi et al., 2009). IL-10 inhibited 
the accumulation of Pol II in the distal regions of TNF, IL6, and 
NFKBIZ, but not NFKBIA (Fig. 1 D), mirroring its effects on 
the corresponding mRNAs (Fig. 1 A). Nascent unspliced TNF 
transcripts were also quantified by PCR (Fig. S1 A) and were 
seen to accumulate with identical kinetics to those of mature   
TNF mRNA in these cells. As estimated by both of these   
methods, IL-10 decreased transcription of TNF (Fig. 1 D and 
Fig. S1 A). These findings in human macrophages are consistent 
with previous reports describing IL-10’s gene-specific effects on 
transcription (Lang et al., 2002; Murray, 2005).
Activation of transcription elongation has recently emerged 
as an important mechanism controlling the rapid induction of 
proinflammatory genes (Adelman et al., 2009; Hargreaves   
et al., 2009; Ramirez-Carrozzi et al., 2009). We therefore in-
vestigated whether IL-10 inhibits transcription elongation by JEM VOL. 207, September 27, 2010  2083
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that lacked the additional genomic sequence, IL-10–dependent 
inhibition was lost (Fig. 3 A and Fig. S2 A). This also resulted in 
a partial loss of LPS responsiveness, indicating that the 3 down-
stream region may contribute to TNF transcriptional control.
The downstream 3 region of the TNF gene is known to 
contain the NF-B binding site B4 (Tsytsykova et al., 2007; 
Krausgruber et al., 2010). Although it is well documented that 
NF-B  plays  a  role  in  TNF  transcription  in  macrophages 
of posttranscriptional control; however, on closer inspection, 
the construct in question, 5luc3(1037) (Fig. 3 A), was found 
to include both the 785-bp TNF 3UTR and an additional 
250 bp of downstream genomic sequence (originally included 
in the construct for ease of cloning). We hypothesized that 
this 250-bp region, rather than the 3UTR, could have medi-
ated  the  IL-10–dependent  inhibition  of  5luc3(1037).   
Indeed, when this construct was compared with a 5luc3(785) 
Figure 1.  IL-10 inhibits proinflammatory gene transcription. (A) Cells were treated with LPS with or without IL-10 for 30 or 120 min. RNA was 
isolated and used in quantitative RT-PCR with probes specific for the indicated mRNA. (B) Position of PCR primers for detecting downstream Pol II at the 
TNF, IL6, NFKBIA, and NFKBIZ genes. (C) Cells were stimulated for the indicated times with LPS, followed by ChIP using Pol II antibodies (filled bars) or  
a rabbit isotype control (open bars) at downstream regions of the TNF and IL6 genes. (D) Cells were treated with LPS with or without IL-10 for 30 or  
120 min and Pol II was measured by ChIP at the downstream regions of TNF, IL6, NFKBIZ, and NFKBIA. Data in A and C are expressed as mean ± SD of tripli-
cate measurements for a single donor, representative of three independent experiments using different donors. Data in D are pooled data from three 
donors and are expressed as mean ± SEM. Statistical significance was assessed using the paired Student’s t test. *, P < 0.05; NS (not significant).2084 IL-10 inhibits transcription elongation of TNF | Smallie et al.
RelA knockdown was then determined on the LPS induction 
of TNF (Fig. 3 C), as well as IL-6, IB-, and IB- mRNA 
(Fig. S2 B), and on the secretion of TNF and IL-6 protein 
(Fig. S2 C), and it could be seen that their expression was   
dependent on RelA. This, along with the fact that the IL-10–
sensitive downstream 3 region of the TNF gene contains the B4 
binding site, prompted us to explore previously unexamined 
aspects of NF-B signaling that IL-10 may regulate. To examine 
(Foxwell et al., 1998; Udalova et al., 2000), previously we and 
others were unable to demonstrate any IL-10–dependent sup-
pression of NF-B activity (Denys et al., 2002; Murray, 2005). 
Therefore, to establish to what extent NF-B contributes to-
ward TNF transcription, we depleted the levels of RelA pro-
tein using a small interfering (si) RNA approach, which was 
recently optimized for primary human macrophages in our 
laboratory (Behmoaras et al., 2008; Fig. 3 B). The effect of 
Figure 2.  IL-10 inhibits transcription elongation at TNF. (A and B) Cells were treated with LPS with or without IL-10 for 30 min followed by ChIP 
using Pol II, phospho-Ser2–specific, or rabbit isotype control antibodies at the TSS or downstream regions of the TNF (A) or NFKBIA (B) genes. (C) Cells 
were left unstimulated or preincubated for 30 min with 500 nM flavopiridol, followed by LPS stimulation for 30 min, and then subjected to ChIP. (D) ChIP 
assay of CDK9 recruitment to the start of the TNF or NFKBIA genes upon stimulation with LPS with or without IL-10. Data are expressed as mean ± SD of 
triplicate measurements for a single donor, representative of three independent experiments using different donors.JEM VOL. 207, September 27, 2010  2085
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Figure 3.  IL-10 inhibits the recruitment of RelA to proinflammatory genes. (A–C) Adenovirus reporters based on the human TNF gene were infected into 
macrophages and stimulated with LPS with or without IL-10 for 4 h, after which luciferase assays were performed. Cells were either transfected with scrambled 
control oligonucleotides (siControl) or RelA-specific siRNA (siRelA; A), and cytoplasmic extracts were subjected to Western blotting using anti-RelA or tubulin anti-
bodies to evaluate the extent of RelA knockdown (B) or cells were stimulated for the indicated times with LPS and total RNA was isolated and used as template in a 
quantitative RT-PCR gene expression assay for TNF mRNA (C). (D) Position of primers used in ChIP assays for the detection of RelA recruitment to the human TNF 
gene. NF-B sites are indicated below the diagram, with the PCR targets represented by black lines with the length of the amplicons indicated above. (E) Cells were 
stimulated with LPS with or without IL-10 for 60 min, after which ChIP assays were performed using RelA-specific antibodies. Data are expressed as mean ± SD of 
triplicate measurements for a single donor representative of eight (A) or three (C and E) independent experiments using different donors.2086 IL-10 inhibits transcription elongation of TNF | Smallie et al.
Considering that IL-10 inhibits RelA 
recruitment  to  the  TNF  gene,  we 
wondered whether depletion of RelA 
in our experimental system could rep-
licate the effects of IL-10 on transcrip-
tion elongation. As expected, using an RNAi approach to deplete 
RelA, after LPS stimulation no RelA was detected to the TNF 
downstream region containing the B4 site (Fig. 4 A). Concomi-
tantly, Rel A depletion had no significant effect on the recruit-
ment of total Pol II to the start of TNF, yet it did result in an 
inability of LPS to induce its progression down the length of 
TNF (Fig. 4 B). This also coincided with a loss of inducible phos-
phorylation of Pol II at Ser2, and an inability to recruit CDK9 to 
the start of TNF in RelA-depleted macrophages (Fig. 4 C). These 
data show that artificial inhibition of RelA recruitment to its target 
B sites replicates IL-10’s effects on TNF transcription elongation.
It is notable that IL-10 also inhibited the recruitment of 
RelA to the NFKBIA B site, despite the fact that transcrip-
tion of this gene is spared from inhibition. The fact that neither 
CDK9 recruitment nor Pol II Ser2 phosphorylation was inhib-
ited by IL-10 at NFKBIA suggests that CDK9 recruitment 
here is independent of RelA. Certain aspects of these data bear 
resemblance to a study of the gene-specific actions of gluco-
corticoids on CDK9 recruitment, where inhibition was ob-
served at the gene coding for IL-8 but not at NFKBIA (Luecke 
and Yamamoto, 2005). The up-regulation of IB- is part of 
a negative-feedback loop that limits inflammatory responses; 
therefore, it is unsurprising that this escapes negative regulation 
by IL-10 and dexamethasone.
To conclude, we provide novel insights into the mecha-
nisms  of  the  IL-10  antiinflammatory  response.  We  have 
shown for TNF that IL-10 predominantly inhibits transcrip-
tion through a unique mechanism targeting the rapid and im-
mediate induction of transcription elongation by Pol II. IL-10 
achieves this in a gene-specific manner through the inhibition 
of RelA-mediated recruitment of CDK9 to the TNF but not 
the NFKBIA promoter, thus preventing the phosphorylation 
of RNA Pol II at Ser2. This study, performed entirely in the 
physiologically relevant primary human macrophage, has   
effects on the nuclear translocation of RelA, we compared 
nuclear versus cytoplasmic protein fractions from macrophages 
stimulated with LPS or IL-10 and found no major role for   
IL-10 in preventing RelA nuclear translocation (Fig. S3). The 
posttranslational modification, by means of LPS-induced 
phosphorylation of RelA Ser536 (a known mark of RelA 
function), was also unaffected (Fig. S3). We also rechecked 
whether IL-10 modulated the LPS-induced degradation and 
resynthesis of IB- in the cytoplasm of human macrophages 
yet found no effect, which is consistent with previous findings 
in mouse macrophages (Murray, 2005).
We then went on to examine the actual recruitment of 
NF-B to B binding sites at proinflammatory genes using 
ChIP. Initially the kinetics of RelA recruitment was assessed in 
these cells (Fig. S4 A). We observed a time-dependent tran-
sient recruitment of RelA to the B sites of the TNF gene 
peaking at 60 min after LPS stimulation. IL-10 inhibited the 
recruitment of RelA to all of the regions in the TNF gene 
containing B sites (Fig. 3 E), including the downstream re-
gion containing B4 (Fig. 3 D). As a control, PCR was per-
formed using primers within the TNF introns (Fig. 3 D,   
region D), where no B sites were found and no recruitment 
was seen at this position, confirming the specificity of the assay.
To ascertain whether the IL-10 inhibition of RelA recruit-
ment occurred at additional genes, we performed similar analy-
sis at the B sites in the NFKBIA, TNFAIP3, and CCL20 
promoters, to which RelA was similarly inhibited (Fig. S4 B) 
This also occurred at the IL6 B site (albeit with later kinetics 
of recruitment; Fig. S4 C). It therefore appears that the mecha-
nism elicited by IL-10 is a widespread block in recruitment of 
RelA to B sites in the genome.
Numerous studies have shown a role for RelA in the activa-
tion of CDK9-mediated control of transcription elongation in   
alternate systems (Barboric et al., 2001; Huang et al., 2009).   
Figure 4.  IL-10 inhibition of elongation 
at TNF is RelA dependent. (A and B) Cells 
were transfected with a siControl or siRelA 
oligonucleotides. Cells were stimulated with 
LPS with or without IL-10 for 1 h, after which 
ChIP was performed using RelA-specific anti-
bodies and primers designed to the B4 site of 
TNF (A) or Pol II–specific antibodies and prim-
ers specific for the TNF TSS or downstream 
regions (B). (C) Cells were treated with or with-
out LPS for 1 h and ChIP was performed using 
Pol II–specific (left), phosphor-Ser2 (middle), or 
CDK9 (right) antibodies and primers specific 
for the TNF TSS+1. Data are expressed as  
mean ± SD of triplicate measurements for a 
single donor representative of three indepen-
dent experiments using different donors.JEM VOL. 207, September 27, 2010  2087
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IgG (GE Healthcare) were used as secondary antibodies at a dilution of 1:2,000. 
Bound antibody was detected using the enhanced chemiluminescence kit   
(GE Healthcare) and visualized using Hyperfilm MP (GE Healthcare).
Quantization of gene expression by real-time PCR. RNA was extracted 
from macrophages using the Blood RNA extraction kit (QIAGEN), and PCR 
reactions were performed and measured on a Corbett Rotor-Gene 6000   
(QIAGEN) using the Superscript III platinum one-step RT-PCR kit (Invitrogen) 
and Assay-On-Demand premixed Taqman probe master mixes(Applied Biosys-
tems). The relative gene expression was calculated using the Ct method with 
the GAPDH gene for normalization of RNA levels. Primary transcript PCR 
was performed as follows: contaminating genomic DNA was removed from 
RNA samples using TURBO DNA-free kit (Applied Biosystems). The proce-
dure routinely removed DNA contamination to levels below the detection lim-
its  of  a  standard  real-time  PCR.  Reverse  transcription  of  total  RNA  was 
performed at 42°C for 2 h with reagents purchased from Promega, followed by 
heat inactivation at 65°C for 10 min to inactivate the enzyme. cDNA was then 
subjected to real-time PCR analysis using SYBR Premix Ex Taq (Lonza). The 
primers  used  for  measuring  primary  transcript  and  mature  transcripts  were   
5-GCAGTCAGATCATCTTCTCG-3 and 5-AGGTACAGGCCCTCT-
GATGGCAC-3  and  5-CCTGCTGCACTTTGGAGTGATCGG-3  and 
5-GTACAGGCCCTCTGATGGCACCACC-3, respectively.
ChIP. Macrophages were plated in 10-cm dishes for culture at 8.5 × 105 cells 
per dish. After stimulation, the cells were fixed for 10 min with formaldehyde 
(37% stock solution; Sigma-Aldrich) at a concentration of 1% and quenched 
using 125 mM Tris, pH 7.5. The nuclei were sonicated using conditions opti-
mised for primary human macrophages. Extracts were precleared for 2 h once 
with 60 µl of a 50% suspension of salmon sperm-saturated protein G (GE 
Healthcare) and again with another 60 µl of protein G and 2 µg ChIP-grade 
rabbit isotype control antibody (Abcam). Immunoprecipitations were per-
formed at 4°C overnight. Immunocomplexes were then collected with pro-
tein G Sepharose beads for 30 min, rigorously washed, and eluted. Protein 
DNA cross-links were reversed by heat at 65°C for 4 h, and DNA was purified 
using the QIAquick PCR Purification kit (QIAGEN) and subjected to real-
time PCR analysis using SYBR Premix Ex Taq. Primer pairs used for ChIP in 
this study were optimised and shown to amplify with similar efficiencies.
Luciferase assays. After stimulation, the amount of GFP fluorescence was 
measured using a FLUOstar Omega plate reader (BMG Labtech) for nor-
malizing the levels of viral infection. Luciferase activity was measured with a 
Labsystem luminometer after the addition of 30 µl luciferin (Bright-Glo   
luciferase assay system; Promega) per well. Levels of luciferase were then 
normalised to the amounts of GFP.
siRNA. Macrophages were transfected with siRNA (Thermo Fisher Scientific) 
targeted to either RelA (RelA) or a nonspecific scrambled control (siControl), 
using methods previously devised and published (Behmoaras et al., 2008).
ELISA. The concentration of TNF and IL-6 in cell culture supernatants was deter-
mined by ELISA (BD), according to the manufacturer’s instructions. Absorbance 
was read and analyzed at 450 nm on a spectrophotometric ELISA plate reader (Lab-
systems Multiskan Biochromatic) using Ascent software (version 2.4.2).
Online supplemental material. Fig. S1 shows that IL-10 inhibits tran-
scription elongation at TNF. Fig. S2 shows that IL-10 requires elements 3 
and downstream of the TNF 3UTR for inhibition. Fig. S3 shows that IL-10 
does not inhibit NF-B activation. Fig. S4 shows that IL-10 inhibits the re-
cruitment of RelA to proinflammatory genes. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20100414/DC1.
This paper is dedicated to the late Professor Brian Foxwell, who was the driving 
force behind this work.
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addressed long-standing contradictions within the field. The 
discovery of a unique negative regulatory checkpoint within 
the  human  innate  immune  system  (CDK9  modulation  of 
transcription elongation) has implications for the development 
of therapeutics that harness the central role that IL-10 plays in 
the suppression of inflammatory processes in humans.
MATERIALS AND METHODS
Reagents. IL-10 was a gift (Schering Plough), macrophage CSF (M-CSF) 
was a gift (Pfizer), and LPS was purchased (Enzo Life Sciences, Inc). Flavo-
piridol (Enzo Life Sciences, Inc.) was used at a 500-nM concentration for   
30 min before stimulation with LPS.
Cells. Single-donor platelet phoresis residue packs were purchased from the 
North London Blood Transfusion Service. Mononuclear cells were isolated by 
Ficoll-Hypaque centrifugation (specific density, 1.077 g/ml) preceeding T cell/
monocyte separation in a JE6 elutriator (Beckman Coulter). T cell purity was as-
sessed by flow cytometry using directly conjugated anti-CD3 (BD), and mono-
cyte purity, assessed using anti-CD45 and anti-CD14 antibodies (Leucogate; 
BD), was routinely >90%. All media and sera were routinely tested for endo-
toxin using the Limulus amebocyte lysate test (BioWhittaker; Lonza) and were 
rejected if the endotoxin concentration exceeded 0.1 U/ml. Macrophages were 
derived from elutriated monocytes by culturing the cells with M-CSF at 
100 ng/ml (Pfizer) in 10% heat-inactivated FCS RPMI 1640 for 3 d.
Antibodies. The anti-IB (C-15) antibody, anti–RNA Pol II, and anti-
CDK9 (H-169) were purchased from Santa Cruz Biotechnology, Inc. Anti-
tubulin was purchased from Sigma-Aldrich. Anti-lamin A/C was purchased 
from BD. Anti Cox-2 was purchased from Cayman Chemical. The anti-Pol 
II CTD phosphor-Ser2, rabbit isotype control antibody, and anti-p65 were 
all purchased from Abcam.
Adenoviral constructs. The TNF-luciferase reporters AdV.Luc.5only and 
AdV.Luc.3(1037) were generated as previously described (Denys et al., 2002). 
The AdV.Luc.3(785) vector was generated by PCR using the primer pairs   
5-CAGTCTAGAGAGGACGAACATCCAACCTTC-3  and  5-CGAG-
TCGACGCAAACTTTATTTCTCGCCAC-3. The PCR product was 
cloned from the pCRII-TOPO TA vector using XbaI and SpeI into the 3 re-
gion of the pAdTrack vector used to make the AdV.Luc.5only virus. This was 
used to generate the adenoviral vector by homologous recombination with 
the pADeasy vector in Escherichia coli BJ cells and purified as per previously de-
vised methods (He et al., 1998). Macrophages were infected with virus at a 
multiplicity of infection of 100 as previously described (Foxwell et al., 1998).
Nuclear extractions and Western blot analysis. After stimulation, cells 
were scraped into ice-cold PBS and then resuspended in hypotonic lysis buffer 
(10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EGTA, 0.1 M EDTA, 1 mM 
NaV03, 0.5 mM NaF, 1 mM PMSF, protease inhibitor tablet, and 1 mM 
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